{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010987","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.379556+00:00","generated_at":"2026-06-14T02:56:03.952150+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aclaris CSO Joseph Monahan shifts to part-time; base salary reduced to $280,800","bullets":["Monahan will serve as Chief Scientific Officer at 60% of full-time schedule as of July 1, 2023.","Annual base salary reduced to $280,800; annual bonus eligibility pro-rated for part-time service.","Amended employment agreement has initial two-year term with automatic one-year renewals unless 90-day notice given.","Monahan remains in role; prior agreement superseded."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010987","json":"https://secwatch.observer/filing/0001558370-23-010987.json","markdown":"https://secwatch.observer/filing/0001558370-23-010987.md","text":"https://secwatch.observer/filing/0001558370-23-010987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023010987/0001558370-23-010987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023010987/acrs-20230609x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:56:03.952150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e1c49c007","claim":"Joseph Monahan changed role as Chief Scientific Officer at Aclaris Therapeutics, Inc..","evidence_excerpt":"Dr. Monahan will continue to serve as the Company’s Chief Scientific Officer but will shift to part-time status, pursuant to which he will provide services at 60% of a full-time schedule.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023010987/0001558370-23-010987-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"Shift to part-time status"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}